BRPI0817396C8 - composição farmacêutica para tratar deficiência de vitamina b¹² - Google Patents

composição farmacêutica para tratar deficiência de vitamina b¹²

Info

Publication number
BRPI0817396C8
BRPI0817396C8 BRPI0817396A BRPI0817396A BRPI0817396C8 BR PI0817396 C8 BRPI0817396 C8 BR PI0817396C8 BR PI0817396 A BRPI0817396 A BR PI0817396A BR PI0817396 A BRPI0817396 A BR PI0817396A BR PI0817396 C8 BRPI0817396 C8 BR PI0817396C8
Authority
BR
Brazil
Prior art keywords
deficiency
vitamin
pharmaceutical composition
individual
treating
Prior art date
Application number
BRPI0817396A
Other languages
English (en)
Portuguese (pt)
Inventor
Castelli Cristina
Kragie Laura
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0817396(C8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of BRPI0817396A2 publication Critical patent/BRPI0817396A2/pt
Publication of BRPI0817396B1 publication Critical patent/BRPI0817396B1/pt
Publication of BRPI0817396B8 publication Critical patent/BRPI0817396B8/pt
Publication of BRPI0817396C1 publication Critical patent/BRPI0817396C1/pt
Publication of BRPI0817396C8 publication Critical patent/BRPI0817396C8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0817396A 2007-11-02 2008-10-31 composição farmacêutica para tratar deficiência de vitamina b¹² BRPI0817396C8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US98489807P 2007-11-02 2007-11-02
US60/984,898 2007-11-02
US2010808P 2008-01-09 2008-01-09
US61/020,108 2008-01-09
US8356608P 2008-07-25 2008-07-25
US61/083,566 2008-07-25
PCT/US2008/082064 WO2009059188A1 (en) 2007-11-02 2008-10-31 Method of treating vitamin b12 deficiency

Publications (5)

Publication Number Publication Date
BRPI0817396A2 BRPI0817396A2 (pt) 2015-04-07
BRPI0817396B1 BRPI0817396B1 (pt) 2019-04-24
BRPI0817396B8 BRPI0817396B8 (pt) 2020-02-04
BRPI0817396C1 BRPI0817396C1 (pt) 2020-11-17
BRPI0817396C8 true BRPI0817396C8 (pt) 2021-05-25

Family

ID=40591491

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817396A BRPI0817396C8 (pt) 2007-11-02 2008-10-31 composição farmacêutica para tratar deficiência de vitamina b¹²

Country Status (18)

Country Link
US (3) US8022048B2 (enExample)
EP (1) EP2215047B1 (enExample)
JP (1) JP5555634B2 (enExample)
KR (1) KR101344369B1 (enExample)
CN (1) CN101952241B (enExample)
AU (1) AU2008318423B2 (enExample)
BR (1) BRPI0817396C8 (enExample)
CA (1) CA2704780C (enExample)
CL (1) CL2010000434A1 (enExample)
CO (1) CO6280475A2 (enExample)
DK (1) DK2215047T3 (enExample)
ES (1) ES2443817T3 (enExample)
MX (1) MX2010004716A (enExample)
NZ (1) NZ585080A (enExample)
PL (1) PL2215047T3 (enExample)
PT (1) PT2215047E (enExample)
RU (1) RU2469728C2 (enExample)
WO (1) WO2009059188A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5985985B2 (ja) * 2009-08-03 2016-09-06 エミスフィアー テクノロジーズ インコーポレイテッドＥｍｉｓｐｈｅｒｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ，Ｉｎｃ． 胃腸への影響が減少した即効型ナプロキセン組成物
KR20130026429A (ko) * 2010-02-24 2013-03-13 에미스페어 테크놀로지스, 인코포레이티드 경구 ｂ12 치료요법
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
EP2696687B1 (en) 2011-04-12 2016-10-26 Novo Nordisk A/S Double-acylated glp-1 derivatives
US8805208B2 (en) * 2012-02-03 2014-08-12 Tyco Electronics Subsea Communications Llc System and method for polarization de-multiplexing in a coherent optical receiver
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
US20140309270A1 (en) 2013-04-11 2014-10-16 Richard Louis Price Diagnosis and treatment of a form of autistic spectrum disorder
US9211284B2 (en) 2013-04-11 2015-12-15 Richard Louis Price Diagnosis and treatment of P.R.I.C.E. syndrome
US20170348417A1 (en) 2013-04-11 2017-12-07 Richard Louis Price Treatment of attention deficit disorders and associated symptoms
US9603812B2 (en) 2013-04-11 2017-03-28 Richard Louis Price Treatment of autistic spectrum disorder
US10098848B2 (en) 2013-04-11 2018-10-16 Richard Louis Price Inositol-containing comestible units and methods of treatment using the same
BR112015026325A2 (pt) 2013-05-02 2017-07-25 Novo Nordisk As dosagem oral de compostos glp-1
MX382853B (es) 2016-04-22 2025-03-13 Spoke Sciences Inc Compuestos medicinales y suplementos nutricionales de base vegetal de rápida acción.
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
US20200254041A1 (en) * 2017-10-05 2020-08-13 Receptor Holdings, Inc. Rapid onset and extended action plant-based and synthetic cannabinoid formulations
US20200268821A1 (en) * 2017-10-05 2020-08-27 Receptor Holdings, Inc. Herbal compositions with improved bioavailability
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
AU2019385420A1 (en) 2018-11-19 2021-07-08 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CA2266412A1 (en) * 1996-09-18 1998-03-26 William J. Sarill Compositions containing cobalamin and amino acids
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
MXPA01006297A (es) * 1998-12-28 2002-06-04 Biogentec Inc Tratamiento con cianocobalamina (vitamina b12) para enfermedades alergicas.
IL145546A0 (en) 1999-04-05 2002-06-30 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
EP1535625B1 (en) 1999-04-05 2014-01-08 Novartis AG Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin
JP4799794B2 (ja) * 2000-03-21 2011-10-26 エミスフェアー・テクノロジーズ・インク ジカルボキシル化中間体を介してアルキル化サリチルアミドを調製する方法。
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
CA2446929C (en) 2001-06-01 2013-04-09 Novartis Ag Orally administering parathyroid hormone and calcitonin
JP4959917B2 (ja) 2001-08-17 2012-06-27 ノバルティス アーゲー 副甲状腺ホルモンフラグメント用経口送達剤としての５−ｃｎａｃ
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
AR040737A1 (es) 2002-08-01 2005-04-20 Novartis Ag Administracion oral de calcitonina
EP1545477A4 (en) 2002-09-13 2006-11-22 Cydex Inc CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN
CN100579955C (zh) 2003-04-04 2010-01-13 帝斯曼知识产权资产管理有限公司 N-烷氧基草酰丙氨酸酯的制备方法
US6938439B2 (en) 2003-05-22 2005-09-06 Cool Clean Technologies, Inc. System for use of land fills and recyclable materials
JP3924616B2 (ja) 2003-06-30 2007-06-06 独立行政法人物質・材料研究機構 微小サイズの温度感知素子を用いる温度計測方法
EP1643978A1 (en) 2003-07-04 2006-04-12 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
WO2005004900A1 (en) * 2003-07-11 2005-01-20 Novartis Ag Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
US7749954B2 (en) 2003-07-23 2010-07-06 Novartis Ag Use of calcitonin in osteoarthritis
JP4903690B2 (ja) * 2004-05-06 2012-03-28 エミスフェアー・テクノロジーズ・インク Ｎ−［８−（２−ヒドリキシベンゾイル）アミノ］カプリル酸一ナトリウムの結晶多形体
WO2006020291A2 (en) * 2004-08-02 2006-02-23 Bebaas, Inc. Vitamin b12 compositions
JP2008509933A (ja) 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427600D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
CA2626029A1 (en) * 2005-11-04 2007-05-18 Genta Incorporated Pharmaceutical gallium compositions and methods

Also Published As

Publication number Publication date
MX2010004716A (es) 2010-12-17
KR20100126263A (ko) 2010-12-01
AU2008318423B2 (en) 2013-12-05
CA2704780A1 (en) 2009-05-07
EP2215047A1 (en) 2010-08-11
BRPI0817396C1 (pt) 2020-11-17
US8288360B2 (en) 2012-10-16
JP5555634B2 (ja) 2014-07-23
HK1146480A1 (en) 2011-06-10
AU2008318423A1 (en) 2009-05-07
US8557792B2 (en) 2013-10-15
CN101952241B (zh) 2014-06-11
RU2469728C2 (ru) 2012-12-20
BRPI0817396B8 (pt) 2020-02-04
PT2215047E (pt) 2014-01-20
CO6280475A2 (es) 2011-05-20
US8022048B2 (en) 2011-09-20
CN101952241A (zh) 2011-01-19
CL2010000434A1 (es) 2011-01-28
DK2215047T3 (da) 2014-02-03
BRPI0817396A2 (pt) 2015-04-07
JP2011502997A (ja) 2011-01-27
ES2443817T3 (es) 2014-02-20
NZ585080A (en) 2012-05-25
US20110293589A1 (en) 2011-12-01
KR101344369B1 (ko) 2013-12-24
EP2215047A4 (en) 2010-11-10
RU2010118423A (ru) 2011-12-10
WO2009059188A1 (en) 2009-05-07
EP2215047B1 (en) 2013-11-20
US20100016255A1 (en) 2010-01-21
BRPI0817396B1 (pt) 2019-04-24
US20130040910A1 (en) 2013-02-14
CA2704780C (en) 2014-06-10
PL2215047T3 (pl) 2014-05-30

Similar Documents

Publication Publication Date Title
BRPI0817396C8 (pt) composição farmacêutica para tratar deficiência de vitamina b¹²
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
MX344787B (es) Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
ATE494889T1 (de) Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
NZ744233A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
BR112018068784A2 (pt) método para o tratamento de leucemia
CL2021003474A1 (es) Producto farmacéutico para terapia enzimática para tratamiento de homocistinuria
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
CL2021000882A1 (es) Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.
RU2008148597A (ru) Фармацевтические комбинации
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
MX2013014071A (es) Combinacion de tratamiento de sinergia para el tratamiento del carcinoma de celula escamosa de cabeza y cuello.
BR112015023368A2 (pt) método de tratamento de deficiência de vitamina b12
UA115250C2 (uk) Фармацевтичні комбінації
NZ701274A (en) Oral b12 therapy
BR112018074434A2 (pt) composições farmacêuticas compreendendo safinamida
CO6331430A2 (es) Composicion farmaceutica que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b para el tratamiento de la neuralgia
BR112023023715A2 (pt) Pluralidade de partículas compreendendo tasquinimod, composição farmacêutica, unidade de dosagem farmacêutica, uso da pluralidade de partículas ou da composição farmacêutica, e, método para o tratamento do câncer
BRPI0517241A (pt) composição farmacêutica, e, método para preparar a mesma
BR112018072583A2 (pt) composição farmacêutica de comprimido em comprimido estável

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2520 DE 25/04/2019 QUANTO AO INVENTOR.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2520 DE 24/04/2019 QUANTO AO PRAZO DE VALIDADE.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2746 DE 22-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.